SG11201403443WA - Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides - Google Patents

Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Info

Publication number: SG11201403443WA
Authority: SG; Singapore
Prior art keywords: polypeptides; expression vector; vector element; cell generation; generation methods
Prior art date: 2011-12-22

Application number

SG11201403443WA

Inventor

Peter Michael Huelsmann

Hendrik Knoetgen

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-19Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche

2014-07-30Publication of SG11201403443WApublicationCriticalpatent/SG11201403443WA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SG11201403443WA2011-12-222012-12-19Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptidesSG11201403443WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11195361		2011-12-22
PCT/EP2012/076203WO2013092743A2 (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number	Publication Date
SG11201403443WAtrue SG11201403443WA (en)	2014-07-30

Family

ID=47504950

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201700169PASG10201700169PA (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
SG11201403443WASG11201403443WA (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
SG10201900915WASG10201900915WA (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10201700169PASG10201700169PA (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201900915WASG10201900915WA (en)	2011-12-22	2012-12-19	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Country Status (14)

Country	Link
US (2)	US20160208284A1 (en)
EP (2)	EP3354660A1 (en)
JP (4)	JP6096802B2 (en)
KR (4)	KR102166824B1 (en)
CN (4)	CN107119073A (en)
BR (1)	BR112014014239B1 (en)
CA (2)	CA3149402A1 (en)
ES (1)	ES2930215T3 (en)
HR (1)	HRP20221383T1 (en)
MX (2)	MX370481B (en)
PL (1)	PL2794651T3 (en)
RU (2)	RU2639519C2 (en)
SG (3)	SG10201700169PA (en)
WO (1)	WO2013092743A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201700169PA (en)*	2011-12-22	2017-02-27	Hoffmann La Roche	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP3059319A4 (en)*	2013-10-07	2017-04-26	Prestige Biopharma Pte. Ltd.	Bicistronic expression vector for antibody expression and method for producing antibody using same
CN105255867A (en)*	2015-10-19	2016-01-20	北京益生合生物科技有限公司	Gene sequence capable of preventing gradual inactivation of promoter in subculture and applications of gene sequence
US11261462B2 (en)	2016-01-27	2022-03-01	Just-Evotec Biologics, Inc.	Inducible expression from transposon-based vectors and uses
US11098310B2 (en)	2016-01-27	2021-08-24	Just-Evotec Biologics, Inc.	Expression from transposon-based vectors and uses
ES2823173T3 (en)	2016-01-27	2021-05-06	Just Biotherapeutics Inc	Hybrid promoter and uses of it
CA3039673A1 (en)	2016-10-20	2018-04-26	Sangamo Therapeutics, Inc.	Methods and compositions for the treatment of fabry disease
WO2018211529A1 (en)*	2017-05-19	2018-11-22	Council Of Scientific & Industrial Research	A method for producing refolded recombinant humanized ranibizumab
JP7081139B2 (en)*	2017-12-20	2022-06-07	東ソー株式会社	New promoter and expression vector containing it
KR20210060561A (en)*	2018-09-20	2021-05-26	사노피	Intron-based universal cloning method and composition
US12421524B2 (en)	2018-09-24	2025-09-23	Merck Sharp & Dohme Llc	Expression vectors for eukaryotic expression systems
EP3870604B1 (en)*	2018-10-26	2022-11-23	F. Hoffmann-La Roche AG	Multispecific antibody screening method using recombinase mediated cassette exchange
KR102798616B1 (en)*	2019-12-20	2025-04-22	(주)셀트리온	Expression cassette for expressing target protein highly and method for using the same
EP4284834A1 (en)	2021-01-29	2023-12-06	Merck Sharp & Dohme LLC	Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2024239229A1 (en)*	2023-05-23	2024-11-28	西安佑佰生物科技有限公司	Vector and method for enhancing transcriptional activity of adjacent promoters
KR102640929B1 (en)	2023-06-02	2024-02-27	(주) 멥스젠	Microphysiological system forming device

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DE3584341D1 (en)	1984-08-24	1991-11-14	Upjohn Co	RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
FI903489A7 (en)	1988-11-11	1990-07-10	Medical Res Council	Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
US5266491A (en)	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (en)	1989-03-14	2000-06-12	持田製薬株式会社	Novel DNA and expression plasmid containing it
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (en)	1990-12-03	1998-05-16	Genentech Inc	ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (en)	1991-10-07	1994-05-27	Oncologix Inc	Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
RU2201449C2 (en)*	1994-10-14	2003-03-27	Сембайозис Дженетикс Инк.	Fused polypeptide able to purposeful transfer to oily body, chimeric dna-construction, expressing cassette
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US5888809A (en)	1997-05-01	1999-03-30	Icos Corporation	Hamster EF-1α transcriptional regulatory DNA
WO1998058964A1 (en)	1997-06-24	1998-12-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
DE69840412D1 (en)	1997-10-31	2009-02-12	Genentech Inc	METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
DK1034298T3 (en)	1997-12-05	2012-01-30	Scripps Research Inst	Humanization of murine antibody
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
KR100797667B1 (en)	1999-10-04	2008-01-23	메디카고 인코포레이티드	How to regulate transcription of foreign genes
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
JP2003516755A (en)	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	Shotgun scanning, a combined method for mapping functional protein epitopes
KR20020093029A (en)	2000-04-11	2002-12-12	제넨테크, 인크.	Multivalent Antibodies And Uses Therefor
KR100408844B1 (en)*	2000-07-29	2003-12-06	한국산업기술평가원	Expression vector using for animal cell
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
ES2405944T3 (en)	2000-11-30	2013-06-04	Medarex, Inc.	Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal micezadas
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7053202B2 (en)	2001-10-19	2006-05-30	Millennium Pharmaceuticals, Inc.	Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
PL213948B1 (en)	2001-10-25	2013-05-31	Genentech Inc	Glycoprotein compositions
EP1308517A1 (en)*	2001-10-31	2003-05-07	Aventis Pharmacueticals Products Inc.	Vectors for expressing multiple transgenes
MXPA04004634A (en)*	2001-11-16	2004-08-12	Idec Pharma Corp	Polycistronic expression of antibodies.
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
JPWO2003085119A1 (en)	2002-04-09	2005-08-11	協和醗酵工業株式会社	Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
PL373256A1 (en)	2002-04-09	2005-08-22	Kyowa Hakko Kogyo Co, Ltd.	Cells with modified genome
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
EP2301966A1 (en)	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
CN100383244C (en)*	2003-01-07	2008-04-23	西福根有限公司	Method for manufacturing recombinant polyclonal proteins
EP1585767A2 (en)	2003-01-16	2005-10-19	Genentech, Inc.	Synthetic antibody phage libraries
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (en)	2003-11-05	2010-05-20	Roche Glycart Ag	FC RECEPTOR AND EFFECTOR FUNCTION
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
CN1961003B (en)	2004-03-31	2013-03-27	健泰科生物技术公司	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
SI2116605T1 (en)*	2004-06-17	2012-07-31	Wyeth Llc	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ATE505552T1 (en)*	2005-10-21	2011-04-15	Hoffmann La Roche	METHOD FOR RECOMBINANT EXPRESSION OF A POLYEPTIDE
ES2577292T3 (en)	2005-11-07	2016-07-14	Genentech, Inc.	Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
JP2009536527A (en)	2006-05-09	2009-10-15	ジェネンテック・インコーポレーテッド	Binding polypeptide with optimized scaffold
US20080124760A1 (en)*	2006-07-26	2008-05-29	Barbara Enenkel	Regulatory Nucleic Acid Elements
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
JP2010512765A (en)*	2006-12-22	2010-04-30	エフ．ホフマン−ラロシュアーゲー	Selection method
WO2008121324A2 (en)*	2007-03-30	2008-10-09	Abbott Laboratories	Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en)	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal display panel driving device and driving method thereof
JP5108942B2 (en)*	2007-06-29	2012-12-26	エフ．ホフマン−ラロシュアーゲー	promoter
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US8227577B2 (en)	2007-12-21	2012-07-24	Hoffman-La Roche Inc.	Bivalent, bispecific antibodies
PL2235064T3 (en)	2008-01-07	2016-06-30	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102197136B (en)*	2008-08-28	2016-09-28	诺华股份有限公司	Cell surface display of polypeptide isoforms read through by stop codons
GB0903207D0 (en)*	2009-02-25	2009-04-08	Ucb Pharma Sa	Method for expressing multimeric proteins
EP2414391B1 (en)	2009-04-02	2018-11-28	Roche Glycart AG	Multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (en)	2009-04-07	2015-04-29	Roche Glycart Ag	Trivalent, bispecific antibodies
ES2439802T3 (en)	2009-05-27	2014-01-24	F. Hoffmann-La Roche Ag	Tri- or tetra-specific antibodies
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
US8703132B2 (en)	2009-06-18	2014-04-22	Hoffmann-La Roche, Inc.	Bispecific, tetravalent antigen binding proteins
SG10201700169PA (en)*	2011-12-22	2017-02-27	Hoffmann La Roche	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

2012
- 2012-12-19SGSG10201700169PApatent/SG10201700169PA/enunknown
- 2012-12-19CACA3149402Apatent/CA3149402A1/enactivePending
- 2012-12-19HRHRP20221383TTpatent/HRP20221383T1/enunknown
- 2012-12-19CNCN201710324350.7Apatent/CN107119073A/enactivePending
- 2012-12-19MXMX2017012736Apatent/MX370481B/enunknown
- 2012-12-19BRBR112014014239-4Apatent/BR112014014239B1/ennot_activeIP Right Cessation
- 2012-12-19KRKR1020197034166Apatent/KR102166824B1/enactiveActive
- 2012-12-19SGSG11201403443WApatent/SG11201403443WA/enunknown
- 2012-12-19KRKR1020147016825Apatent/KR102048556B1/enactiveActive
- 2012-12-19KRKR1020207007391Apatent/KR102229491B1/enactiveActive
- 2012-12-19MXMX2014007359Apatent/MX355624B/enactiveIP Right Grant
- 2012-12-19USUS14/367,680patent/US20160208284A1/ennot_activeAbandoned
- 2012-12-19CNCN202111171021.6Apatent/CN113896787A/enactivePending
- 2012-12-19EPEP18157484.9Apatent/EP3354660A1/enactivePending
- 2012-12-19RURU2014129727Apatent/RU2639519C2/enactive
- 2012-12-19SGSG10201900915WApatent/SG10201900915WA/enunknown
- 2012-12-19JPJP2014547983Apatent/JP6096802B2/enactiveActive
- 2012-12-19EPEP12810245.6Apatent/EP2794651B1/enactiveActive
- 2012-12-19CACA2854249Apatent/CA2854249C/enactiveActive
- 2012-12-19RURU2017140661Apatent/RU2756910C2/enactive
- 2012-12-19WOPCT/EP2012/076203patent/WO2013092743A2/enactiveApplication Filing
- 2012-12-19KRKR1020217007341Apatent/KR102285184B1/enactiveActive
- 2012-12-19CNCN202111170578.8Apatent/CN113881702B/enactiveActive
- 2012-12-19ESES12810245Tpatent/ES2930215T3/enactiveActive
- 2012-12-19CNCN201280062793.9Apatent/CN104011075B/enactiveActive
- 2012-12-19PLPL12810245.6Tpatent/PL2794651T3/enunknown
2017
- 2017-02-16JPJP2017026502Apatent/JP6417436B2/enactiveActive
2018
- 2018-10-05JPJP2018189605Apatent/JP2019030311A/enactivePending
2019
- 2019-12-09JPJP2019221805Apatent/JP7096806B2/enactiveActive
2020
- 2020-07-06USUS16/921,194patent/US20210024952A1/enactivePending

Also Published As

Publication number	Publication date
BR112014014239B1 (en)	2021-10-13
KR102229491B1 (en)	2021-03-18
RU2017140661A3 (en)	2021-08-09
ES2930215T3 (en)	2022-12-07
SG10201700169PA (en)	2017-02-27
KR102166824B1 (en)	2020-10-19
KR20190132702A (en)	2019-11-28
CN113896787A (en)	2022-01-07
JP6417436B2 (en)	2018-11-07
CA2854249C (en)	2022-05-03
MX370481B (en)	2019-12-16
WO2013092743A3 (en)	2013-10-03
HRP20221383T1 (en)	2023-01-06
CN104011075A (en)	2014-08-27
KR20210031002A (en)	2021-03-18
CN107119073A (en)	2017-09-01
US20210024952A1 (en)	2021-01-28
JP6096802B2 (en)	2017-03-15
CN113881702A (en)	2022-01-04
SG10201900915WA (en)	2019-03-28
JP7096806B2 (en)	2022-07-06
CA2854249A1 (en)	2013-06-27
JP2015500656A (en)	2015-01-08
US20160208284A1 (en)	2016-07-21
WO2013092743A2 (en)	2013-06-27
KR102285184B1 (en)	2021-08-03
HK1200848A1 (en)	2015-08-14
BR112014014239A2 (en)	2017-12-26
EP3354660A1 (en)	2018-08-01
EP2794651A2 (en)	2014-10-29
RU2756910C2 (en)	2021-10-06
CN104011075B (en)	2017-06-06
KR20140106585A (en)	2014-09-03
CA3149402A1 (en)	2013-06-27
PL2794651T3 (en)	2022-12-27
CN113881702B (en)	2025-05-30
MX355624B (en)	2018-04-25
JP2017108753A (en)	2017-06-22
KR20200032240A (en)	2020-03-25
JP2020054372A (en)	2020-04-09
RU2014129727A (en)	2016-02-20
JP2019030311A (en)	2019-02-28
EP2794651B1 (en)	2022-09-21
RU2017140661A (en)	2019-02-12
RU2639519C2 (en)	2017-12-21
KR102048556B1 (en)	2019-11-26
MX2014007359A (en)	2014-08-01

Publication	Publication Date	Title
SG11201403443WA (en)	2014-07-30	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
IL271870B (en)	2022-04-01	Factor viii chimeric and hybrid polypeptides, and methods of use thereof
IL260045B (en)	2020-06-30	Polypeptide constructs and uses thereof
ZA201707452B (en)	2021-03-31	Cell culture compositions and methods for polypeptide production
IL222454B (en)	2018-11-29	Process for the production of recombinant polypeptides
EP2839019A4 (en)	2016-03-30	CD3-BINDING POLYPEPTIDES
PL2836511T3 (en)	2018-06-29	Polypeptide useful in adoptive cell therapy
IL222453B (en)	2018-11-29	Process for the production of recombinant polypeptides
SG11201403223PA (en)	2014-07-30	Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
SG11201403814RA (en)	2014-10-30	Production of recombinant proteins with simple glycoforms
HUP1000366A2 (en)	2012-03-28	Novel proteins, their production process and use tereof
SG11201402139UA (en)	2014-06-27	High mast2-affinity polypeptides and uses thereof
HUP1200171A1 (en)	2013-09-30	Methods for the production of polypeptides
SG11201600872UA (en)	2016-03-30	Means and methods for the generation of mammalian producer cells for the production of recombinant proteins
HK40059284B (en)	2025-07-18	Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
IL237100A0 (en)	2015-03-31	Method for the production of polypeptides in the periplasm of prokaryotic cells
HK40091851A (en)	2023-12-15	Factor viii chimeric and hybrid polypeptides, and methods of use thereof
GB201212848D0 (en)	2012-09-05	Stem cell product
GB201205972D0 (en)	2012-05-16	Stem cell product
GB201112985D0 (en)	2011-09-14	Polypeptide
GB201112849D0 (en)	2011-09-07	Polypeptide
GB201106130D0 (en)	2011-05-25	Polypeptide

Movatterモバイル変換

SG11201403443WA - Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=47504950

Family Applications (3)

Family Applications Before (1)

Family Applications After (1)

Country Status (14)

Families Citing this family (16)

Family Cites Families (96)

Also Published As

Similar Documents